The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMPN 2025 | Challenges of managing blast-phase MPNs: the role of transplant, impact of TP53 mutations & more
In this discussion, Adam Mead, MA, BM, BCh, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, Charlotte Brierley, MA, BM BCh, MRCP, DPhil, FRCPath, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, and Juan Carlos Hernández-Boluda, MD, PhD, Hospital Clinic of Valencia, Valencia, Spain, discuss the challenges of managing accelerated and blast-phase myeloproliferative neoplasms (MPNs), highlighting the need for biomarkers to identify patients at risk of aggressive disease progression. They also comment on the role and timing of transplantation for patients, and conclude by discussing the impact of TP53 mutations. This discussion took place at the 3rd International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS & iwMPN) 2025, held in Lisbon, Portugal.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
